This multicenter study evaluated the tolerance and potential pharmacokineti
c interactions between azithromycin and rifabutin in volunteers with or wit
hout human immunodeficiency virus infection. Daily dosing with the combinat
ion of azithromycin and rifabutin was poorly tolerated, primarily because o
f gastrointestinal symptoms and neutropenia. No significant pharmacokinetic
interactions were found between these drugs.